TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Metastatic disease~    * Patients with only bone metastases are not eligible~* Refractory disease, defined as disease progression, drug-related adverse reaction, or disease relapse during or within 12 months after completion of paclitaxel or docetaxel AND doxorubicin or epirubicin administered in the neoadjuvant, adjuvant, or metastatic setting~  * Total neoadjuvant or adjuvant taxane dose \> 700 mg/m\^2 for paclitaxel or \> 240 mg/m\^2 for docetaxel~ * Total taxane dose \> 350 mg/m\^2 for paclitaxel or \> 120 mg/m\^2 for docetaxel in the metastatic setting~ * Total neoadjuvant or adjuvant anthracycline dose \> 240 mg/m\^2 for doxorubicin or epirubicin~ * Total anthracycline dose \> 120 mg/m\^2 for doxorubicin or epirubicin in the metastatic setting~* HER2/neu overexpression~  * 3+ by immunohistochemistry or positive by fluorescence in situ hybridization~* No symptomatic brain metastases~* No pleural or pericardial effusion or ascites~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 20 to 75~Sex~* Female~Menopausal status~* Not specified~Performance status~* ECOG 0-2~Life expectancy~* At least 3 months~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9.0 g/dL~Hepatic~* SGOT or SGPT ≤ 2.0 times upper limit of normal (ULN) (\< 3.0 times ULN for patients with liver metastases)~* Alkaline phosphatase ≤ 2.5 times ULN~* Bilirubin ≤ 1.5 mg/dL~Renal~* Creatinine ≤ 1.2 mg/dL~Cardiovascular~* LVEF \> 50%~Pulmonary~* No interstitial pneumonia with pulmonary fibrosis~Other~* No history of hypersensitivity reactions~* No serious, uncontrolled infection~* No other malignancy~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Prior trastuzumab (Herceptin®) for metastatic disease allowed~Chemotherapy~* See Disease Characteristics~* No prior capecitabine~* At least 2 weeks since prior antimetabolites for metastatic disease~* At least 4 weeks since prior alkylating agents, carcinostatic antibiotics, or other carcinostatic agents~Endocrine therapy~* At least 4 weeks since prior goserelin or leuprolide for metastatic disease~* At least 2 weeks since prior oral endocrine agents for metastatic disease~* No concurrent endocrine therapy~Radiotherapy~* No prior radiotherapy to target lesions~* At least 4 weeks since prior radiotherapy~* No concurrent radiotherapy, including radiotherapy for brain metastases~Surgery~* Not specified~Other~* Concurrent bisphosphonates for bone metastases allowed

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female of any race, at least 18 years of age~* Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)~Exclusion Criteria:~* Patients with other severe pain (eg, Diabetic Peripheral Neuropathy and PostHerpetic Neuralgia) that may confound assessment or self evaluation of the pain associated with fibromyalgia~* Patients with any autoimmune rheumatic disorder, non-focal rheumatic disease (other than fibromyalgia), active infection, or untreated endocrine disorder~* A current or recent diagnosis (last 6 months) or episode of major depressive disorder, dysthymia and/or uncontrolled depression~* History of mania, hypomania, other psychotic disorder, or current mood disorder with psychotic features

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: SHAM_COMPARATOR): None
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 1-3 years~* Fever = or \> 38.0 C and at least one respiratory symptom OR fever = or \> 38.0 C and a positive influenza rapid test~Exclusion Criteria:~* Confirmed infection with any other respiratory virus than influenza.~* Suspicion of invasive bacterial infection requiring immediate admission to hospital~* Evidence of a poorly controlled underlying medical condition~* Known immunosuppression (malignancy, transplant, drugs)~* Known allergy to oseltamivir or paracetamol~* Received oseltamivir within 4 weeks~* Participation in another clinical trial with an investigational drug

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Oseltamivir
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Incl. Criteria Patients with clinical diagnosis of stable Chronic Obstructive Pulmonary Disease (COPD) according to definition of China COPD guideline.~Patients over 40 years old~Exclusion Criteria:~Patient with history of hypersensitivity to tiotropium bromide, atropine and/or its derivant, i.e. ipratropium, or any component of Spiriva® Patient with known narrow-angle glaucoma~* Patient with known symptomatic prostatic hyperplasia and/or bladder-neck obstruction~* Patient with known moderate to severe renal impairment (i.e.,creatinin clearance\<=50ml/min)~* Pregnant or nursing women~* Patient with any significant disease other than COPD which would exclude him/her from participating in the study~* Patients with any conditions listed in \[special precautions\], \[drug interactions\], and \[contraindication\] of Spiriva® China package insert~* Patients with signed informed consent of any other study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin for the Treatment of Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be selected for all studies based on the Rome I criteria. This will be the preferred method of identifying IBS patients to avoid pre-selecting patients with C- IBS. The goal is to evaluate methane as the determinant of transit, not constipation or diarrhea symptoms as through Rome II criteria. All subjects who are receiving a prokinetic drug at the time of enrollment will need to have a washout period of 7 days before starting the study protocol. Subjects will be identified through advertising in printed media and through the clinical operations of the GI motility program at Cedars-Sinai Medical Center.~Exclusion Criteria:~* Subjects with a history of inflammatory bowel disease, diabetes, previous intestinal surgery, cirrhosis, celiac disease, probiotic use, current proton pump inhibitor use, recent antibiotic use (past 3 months), history of bowel obstruction, narcotic use or age greater than 65 years will be excluded. Most of these conditions are known to influence enteric bacteria levels. Women of childbearing years will undergo pregnancy testing before participating in the study (See below for details on the pregnancy test used). Women with positive pregnancy tests will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Memantine Treatment Study of Pathological Gambling

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Pathological Gambling using the clinician-administered Structured Clinical Interview for Pathological Gambling (SCI-PG) (Grant et al., 2004);~* Gambling behavior within 2 weeks prior to enrollment;~* For women, negative results on a urine pregnancy test and stable use of a medically accepted form of contraception.~Exclusion Criteria:~* Infrequent gambling (i.e. less than one time per week) that does not meet DSM-IV criteria for PG;~* Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen;~* History of seizures;~* Myocardial infarction within 6 months;~* Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;~* A need for medication other than memantine with possible psychotropic effects or unfavorable interactions;~* Clinically significant suicidality;~* Current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders (Grant et al., 2005), except for nicotine dependence;~* Lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID;~* Current or recent (past 3 months) DSM-IV substance abuse or dependence;~* Positive urine drug screen at screening;~* Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline;~* Previous treatment with memantine;~* Treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- memantine (Type: EXPERIMENTAL): 10 to 30 mg/day memantine. The study consisted of 10 weeks of open-label memantine. All eligible study subjects were started at 10 mg/day for 2 weeks. The dose was increased to 20 mg/day after 2 weeks and then to 30 mg/day after 4 weeks unless remission of PG symptoms was attained at a lower dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Atorvastatin Pleiotropic Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects of age of majority to \< 80 years~* Subjects with LDL-C \> 0.5 g/L (1.29 mmol/L) and \< 1.5 g/L (3.87 mmol/L), TG \< 4.00 g/L (4.56 mmol/L) and hs-CRP \>1.5 mg/L and \< 15 mg/L~* Subjects with a documented coronary artery disease.~Exclusion Criteria:~* Female subjects of childbearing potential without contraception~* Subjects with secondary hyperlipidemia~* Diabetic subjects receiving insulin~* Subjects with a contra-indication to statin therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed ICF (Informed Consent Form) and HIPAA (Health Insurance Portability and Accountability Act)~* Patient-reported history of DED in both eyes~* Current use of OTC (over-the-counter) and/or artificial tears for dry eye symptoms~* Ability and willingness to follow instructions, including participation in all study assessments and visits~Exclusion Criteria:~* Women who are pregnant, nursing or planning a pregnancy~* Unwillingness to submit a urine pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control~* Clinically significant slit-lamp findings or abnormal lid anatomy at screening~* Ocular/periocular malignancy~* History of herpetic keratitis~* Active ocular allergies or ocular allergies that may become active during the study period~* Ongoing ocular or systemic infection at screening or baseline~* Wear of contact lenses within 3 months prior to screening or anticipated use of contact lenses during the study~* History of no response to previous topical Cyclosporine A and/or use of topical Cyclosporine A or Liftigrast within 2 months prior to screening~* Intraocular surgery or ocular laser surgery within the previous 6 months, or have any planned ocular and/or lid surgeries over the study period~* Presence of uncontrolled systemic diseases~* Presence of known allergy and/or sensitivity to the study drug or its components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CyclASol Ophthalmic Solution (Type: EXPERIMENTAL): Cylclosporine A solution in vehicle
- Vehicle Ophthalmic Solution (Type: PLACEBO_COMPARATOR): Vehicle only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Palliative Care in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Duke University Hospital inpatient adults~* Hospitalization for acute decompensated heart failure~* Dyspnea (shortness of breath) at rest or minimal exertion plus at least 1 sign of volume overload~* Previous heart failure hospitalization within the past 1 year~* At significant risk of dying from heart failure in the next 6 months~* Anticipated discharge from hospital with anticipated ability to return to outpatient follow-up appointments~Exclusion Criteria:~* Are not an inpatient at Duke University Hospital~* Acute coronary syndrome within 30 days~* Cardiac resynchronization therapy (CRT) within the past 3 months or current plan to implant CRT device~* Active myocarditis, constrictive pericarditis~* Severe stenotic valvular disease amenable to surgical intervention~* Anticipated heart transplant or ventricular assist device within 6 months~* Renal replacement therapy~* Non-cardiac terminal illness~* Women who are pregnant or planning to become pregnant~* Inability to comply with study protocol~* Are not proficient in the English language

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual heart failure care (Type: NO_INTERVENTION): Patients will be managed by a cardiologist-directed team with expertise in the diagnosis and treatment of heart failure. Until discharge, inpatient care will focus on symptom relief and initiation of evidence-based therapies. Additional goals of care will include treatment of co-morbidities and patient education designed to assist with self-management techniques. However, after discharge, which is where the study actually takes place, patients will only receive outpatient follow-up with a heart failure cardiologist or nurse practitioner who will focus on medication titration to evidence-based dosing, titration of diuretic therapy, assessment of compliance with medical and dietary regimens, and serial monitoring of end-organ function.
- Usual care + palliative care (Type: ACTIVE_COMPARATOR): Patients will receive an interdisciplinary, multicomponent palliative care intervention combined with state of the art heart failure management designed to assess and manage the multiple domains of quality of life at the end of life for patients with advanced heart failure, including physical symptoms, psychosocial concerns, and spiritual concerns, and to facilitate advance care planning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Etanercept Treatment in the Early Course of Polymyalgia Rheumatica

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Persons with active polymyalgia rheumatica (patients only).~* Signed informed consent and written authorization.~Exclusion Criteria:~* Other inflammatory conditions than polymyalgia rheumatica, including symptoms of giant cell arteritis, e.g. head aches, jaw claudication and visual disturbances.~* Current malignancy or history of malignancy.~* Neuromuscular conditions.~* Infections with systemic impact.~* Uncontrolled diabetes mellitus.~* Uncontrolled hypertension.~* Current tuberculosis or history of tuberculosis.~* Severe heart failure (NYHA class 3 and 4).~* Current use of glucocorticoids, biological drugs, and immunosuppressive drugs.~Exclusion Criteria (controls):~* Polymyalgia rheumatica.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of RA for less than or equal to 3 years~* Be 18 years of age or older at the time of diagnosis~Exclusion Criteria:~* Pregnant or lactating women~* History of chronic infection, such as hepatitis, pneumonia, or chronic skin infections~* Active TB or evidence of latent TB

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): methotrexate (MTX) + etanercept
- 2 (Type: ACTIVE_COMPARATOR): methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
- 3 (Type: ACTIVE_COMPARATOR): methotrexate (MTX) or MTX + Etanercept
- 4 (Type: ACTIVE_COMPARATOR): methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Subjects entering the Treatment Cohort must meet both of the following criteria:~* Completed study visits up to Week 24 of Study 109 or Week 26 of Study 011B and did not permanently discontinue treatment~* Willing to remain on a stable CF medication through the Safety Follow-up Visit.~Subjects entering the Observational Cohort must meet 1 of the following criteria:~* Completed 24 weeks of study drug treatment in Study 109 or completed 24 weeks of study drug treatment and the Week 26 Safety Follow up in Study 011B.~* Received at least 4 weeks of study drug and completed visits up to Week 24 of Study 109 or Week 26 of Study 011B.~Exclusion Criteria (Treatment Cohort Only):~* History of any comorbidity or laboratory abnormality that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject (e.g., cirrhosis with portal hypertension).~* Pregnant and nursing females.~* Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements.~* History of drug intolerance in the prior study that would pose an additional risk to the subject in the opinion of investigator~* History of poor compliance with study drug and/or procedure in the previous study as deemed by the investigator.~* Participation in an investigational drug trial (including studies investigating lumacaftor and/or ivacaftor).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Period 1: LUM/IVA to LUM/IVA (Type: EXPERIMENTAL): None
- Treatment Period 1: Placebo (PBO) to LUM/IVA (Type: EXPERIMENTAL): None
- Treatment Period 1: Observational Cohort (Type: NO_INTERVENTION): None
- Treatment Period 2: LUM/IVA (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete